Filing Flows › Tandem Diabetes Care (TNDM) › Q4 2025
Tandem Diabetes Care (TNDM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 19, 2026
Tandem Diabetes Care (TNDM) reported revenue of $290M for the fourth quarter 2025 (Q4 2025), +3% from a year earlier and +17% from the quarter before. Operating margin was 2.9%, net loss $589K (0.2% of revenue).
Tandem Diabetes Care, Q4 2025: revenue $290M (+3% year over year), operating margin 2.9%, net loss $589K, operating cash flow $9.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $290M | +17% | +3% |
| Operating profit | $8.3M | — | — |
| Net earnings | −$589K | — | — |
| Operating cash flow | $9.8M | +18% | -9% |
| Free cash flow | $3.1M | -26% | -59% |
What changed
Revenue was $290.4M in Q4 2025, up 3% year over year and up 17% from the previous quarter. Supplies and other was the largest line at 52% of revenue.
Gross margin was 57.7%, up 2.0 points from a year earlier. Operating profit was $8.3M, a 2.9% margin (up 3.1 points year over year). Operating expenses grew 1% against revenue growth of 3%. The quarter ended with a net loss of $589K, narrower than the previous quarter's $21.2M loss. Net interest and other expense of $3.6M was the main reason.
Operating cash flow was $9.8M (down 9% year over year). Non-cash charges added back $4.5M of depreciation and amortization and $20.1M of share-based compensation. Working capital and other items used $14.2M. Capital expenditures of $6.7M left free cash flow of $3.1M.
Questions
What was Tandem Diabetes Care's revenue in the fourth quarter 2025?
Tandem Diabetes Care (TNDM) reported revenue of $290M for the fourth quarter 2025 (Q4 2025), +3% from a year earlier and +17% from the quarter before.
Was Tandem Diabetes Care profitable in the fourth quarter 2025?
Operating profit was $8.3M (2.9% of revenue) and net loss $589K.